Late Response to Anti-CGRP Monoclonal Antibodies in Migraine
2023; Lippincott Williams & Wilkins; Volume: 101; Issue: 11 Linguagem: Inglês
10.1212/wnl.0000000000207292
ISSN1526-632X
AutoresPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, Paola Torelli, Stefania Proietti, Sabina Cevoli, Stefano Bonassi, Giulia Fiorentini Psy, Roberta Messina, Bruno Colombo, Florindo d’Onofrio, Maria Albanese, Cinzia Finocchi, Antonio Salerno, B. Mercuri, Antonio Carnevale, Francesco Bono, Fabio Frediani, Licia Grazzi, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri, Marco Aguggia, Davide Bertuzzo, Maurizio Zucco, Laura Di Clemente, Michele Trimboli, Valentina Favoni, Paola Di Fiore,
Tópico(s)Olfactory and Sensory Function Studies
ResumoTo assess the frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP).
Referência(s)